Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome

( views:223, downloads:0 )
Author:
CAO Zheng()
ZHOU Yu-jie()
ZHAO Ying-xin()
LIU Yu-yang()
GUO Yong-he()
CHENG Wan-jun()
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 119, Issue 14, 2006
DOI:
Key Word:
stents;thiazolidinediones;coronary disease;metabolic syndrome

Abstract: Background Recent studies have shown that thiazolidinediones (TZDs) could reduce in-stent restenosis and improve clinical outcomes in patients with type 2 diabetes after coronary stent implantation. It remains unclear whether nondiabetic patients with metabolic syndrome after stenting could also benefit from the treatment with TZDs.Methods Three hundred and sixty patients with metabolic syndrome who underwent coronary stent implantation were randomly assigned to a rosiglitazone group (n=180) or a control group (n=180). Patients in the rosiglitazone treatment group were treated with rosiglitazone 1 day before coronary stenting (4 mg once daily)and treatment was continued until the 9 months follow-up; while in the control group, patients were treated with placebo 1 day before the procedure and until the 9 months follow-up. Adverse events were death, myocardial infarction and urgent target vessel revascularization within 9 months after coronary stenting.Results One hundred and fifty two patients in the rosiglitazone group and 145 patients in the control group survived during the follow-up. Baseline characteristics among patients in the two groups were well balanced.There was no significant difference in target vessels or the procedure of stent implantation. Compared with the control group, treatment with rosiglitazone was associated with a lower rate of death, myocardial infarction and urgent target vessel revascularization (7.2% vs 14.5%, P=0.044).Conclusion Rosiglitazone could reduce the risk of the adverse cardiovascular event and improve clinical outcomes in nondiabetic patients with metabolic syndrome after coronary stent implantation.

  • [1]Mudra H,di Mario C,de Jaegere P,Figulla HR,Macaya C,Zahn R,et al.Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study).Circulation 2001; 104:1343-1349.
  • [2]Hannele YJ.Drug therapy:Thiazolidinediones.N Engl J Med 2004; 351:1106 -1118.
  • [3]Choi D,Kim SK,Choi SH,Ko YG,Jang Y,Lim SK,et al.Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2diabetes.Diabetes Care 2004;27:2654-2660.
  • [4]Takagi T,Akasaka T,Yamamuro A,Honda Y,Hozumi T,Morioka S,et al.Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus:a serialintravascular ultrasound study.J Am Coll Cardiol 2000; 36:1529-1535.
  • [5]Takagi T,Yamamuro A,Tamita K,Yamabe K,Katayama M,Mizoguchi S,et al.Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus:an intravascular ultrasound scanning study.Am Heart J 2003; 146:E5.
  • [6]Ford ES.Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.Diabetes Care 2005; 28:2745-2749.
  • [7]Hak AE,Pols HA,Stehouwer CD,Meijer J,Kiliaan AJ,Hofman A,et al.Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly:the Rotterdam study.J Clin Endocrinol Metab 2001; 86:4398-4405.
  • [8]Lteif A,Mather K.Insulin resistance,metabolic syndrome and vascular diseases:update on mechanistic linkages.Can J Cardiol 2004; 20 Suppl B:66B-76B.
  • [9]Laight DW,Desai KM,Anggard EE,Carrier MJ.Endothelialdysfunction accompanies a pro-oxidant,pro-diabetic challenge inthe insulin resistant,obese Zucker rat in vivo.Eur J Pharmacol 2000; 402:95-99.
  • [10]Haffner SM.Insulin resistance,inflammation,and the prediabetic state.Am J Cardiol 2003; 92:18J -26J.
  • [11]Frederick W,Campbell R.Inflammation and restenosis in the stent era.Arterioscler Thromb Vasc Biol 2002; 22:1769-1776.
  • [12]Monraats PS,Pires N,Agema RP,Zwinderman AH,Schepers A,de Maat MP,et al.Genetic inflammatory factors predict restenosis after percutaneous coronary interventions.Circulation 2005; 112:2417-2425.
  • [13]Costa MA,Simon DI.Molecular basis of restenosis and drug-eluting stents.Circulation 2005; 111:2257-2273.
  • [14]Shah PK.Inflammation,neointimal hyperplasia,and restenosis:As the leukocytes roll,the arteries thicken.Circulation 2003; 107:2175-2177.
  • [15]Jamal SR,Mittleman MA,Ho KK,Cutlip DE.Obesity and clinical restenosis after coronary stent placement.Am Heart J 2005; 150:821-826.
  • [16]Marx N.PPAR γ and vascular inflammation:adding another piece to the puzzle.Circ Res 2002; 91:373-374.
  • [17]Wang TD,Chen W J,Lin JW,Chen MF,Lee YT.Effects of rosiglitazone on endothelial function,C-reactive protein,and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.Am J Cardiol 2004; 93:362-365.
  • [18]Wang G,Wei J,Guan Y,Jin N,Mao J,Wang X.Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.Metabolism 2005;54:590-597.
  • [19]Zahradka P,Yurkova N,Litchie B,Moon MC,Del Rizzo DF,Taylor CG,et al.Activation of peroxisome proliferators-activated receptors α and γ 1 inhibits human smooth muscle cell proliferation.Mol Cell Biochem 2003;246:105-110.
  • [20]Marx N,Schonbeck U,Lazar MA,Libby P,Plutzky J.Peroxisome proliferator activated receptor-γ activators inhibit gene expression and migration inhuman vascular smooth muscle cells.Circ Res 1998;83:1097-1103.
  • [21]Aizawa Y,Kawabe J,Hasebe N,Takehara N,Kikuchi K.Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia.Circulation 2001; 104:455-460.
  • [22]Lebovitz HE,Kreider M,Freed MI.Evaluation of liver function in type 2 diabetic patients during clinical trials:evidence that rosiglitazone does not cause hepatic dysfunction.Diabetes Care 2002; 25:815-821.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn